Far­al­lon says it's won all de­sired board seats from Ex­elix­is af­ter share­hold­er vote

Less than two months af­ter Far­al­lon Cap­i­tal Man­age­ment launched a proxy fight to gain con­trol of three seats on can­cer biotech Ex­elix­is’ board, it got what it want­ed at the com­pa­ny’s an­nu­al share­hold­er meet­ing.

The hedge fund said Wednes­day that pre­lim­i­nary re­sults at Ex­elix­is’ an­nu­al share­hold­er meet­ing elect­ed all three of Far­al­lon’s can­di­dates to the board: Tom Hey­man, Dave John­son and Bob Oliv­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.